Take a sneak peek at the latest updates on the domestic launch of Beizutifan!

Belzutifan is an inhibitor of hypoxia-inducible factor (HIF)-2α, mainly used to treat von Hippel-Lindau disease (VHL)-related diseases. VHL is a rare genetic disease. Patients often develop various types of tumors and cysts due to genetic mutations, including renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastoma, pancreatic tumors, etc. Bestifan inhibits HIF-2α and interferes with the hypoxia-inducible factor pathway, thereby inhibiting the proliferation of tumor cells and delaying tumor progression.

Clinical trials of besetifan have shown that it has significant efficacy in the treatment of a variety of tumors associated with VHL. Especially in patients with renal cell carcinoma (RCC) and central nervous system hemangioblastoma, bezutivan has shown good anti-tumor effects. The indications for bezutivan are not limited to VHL disease, but are also applicable to certain types of adult renal cell carcinoma (RCC). These renal cell carcinomas are usually highly malignant and often associated with metastasis. By inhibiting the HIF-2α pathway, Bestifan can effectively inhibit the proliferation of tumor cells and achieve partial or complete remission in some patients. The drug's mechanism of action is innovative because it can target the hypoxic state in the tumor microenvironment, providing an effective supplement to traditional treatment options.

In China, besotivan has been on the market for a short time, so it is still in an uncertain stage in terms of price and medical insurance policies. At present, the price of imported drugs for besetifan is relatively high, and it has not yet been clearly included in China's national medical insurance catalog. Therefore, if patients want to purchase the drug, they usually need to pay for it at their own expense or purchase the drug cross-border. For patients, with the gradual promotion of besetifan in the Chinese market, more transparent price information and medical insurance policies may appear in the future.

Reference materials:https://www.welireg.com/